SCHEMBL5256019

SCHEMBL5256019

O=C(N[C@H]1CCCC[C@H]1C(=O)O)c1cc2ccccc2[nH]1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCKBR P32239 2/20 0.57
FAAH O00519 1/20 0.54
SSTR3 P32745 1/20 0.54
NPC1 O15118 1/20 0.53
LMNA P02545 1/20 0.53
RAB9A P51151 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
KDM4E B2RXH2 3/20 0.52
ALDH1A1 P00352 1/20 0.52
GAA P10253 1/20 0.52
MAPK1 P28482 1/20 0.52
CHRNA7 P36544 1/20 0.51
HTR3A P46098 1/20 0.51
HPGD P15428 2/20 0.50
HSD17B10 Q99714 2/20 0.50
MAPT P10636 1/20 0.50
DAO P14920 1/20 0.50
SRD5A2 P31213 1/20 0.50
PYGL P06737 1/20 0.50
PYGM P11217 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27558367 1.00 CCKBR (0.57) CCKBRFAAHSSTR3NPC1LMNA
SCHEMBL6834814 0.85 MLLT1 (0.53) CCKBRMLLT1CGASFLT3
SCHEMBL5258969 0.85 MLLT1 (0.53) CCKBRMLLT1CGASFLT3
SCHEMBL18280728 0.85 POLB (0.56) FAAHSSTR3NPC1LMNARAB9A
SCHEMBL14565580 0.84 TAS1R3 (0.52) CCKBRFAAHSSTR3KDM4EALDH1A1
SCHEMBL5260262 0.84 F10 (0.59) PYGLPYGM
SCHEMBL7067623 0.84 MLLT1 (0.72) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL7069488 0.84 SMYD3 (0.61) PYGLMLLT1
SCHEMBL6834302 0.84 DRD4 (0.56) CCKBRPYGLPYGMMLLT1CGAS
SCHEMBL6832859 0.84 MLLT1 (0.52) CCKBRPYGLPYGMMLLT1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1453801-B1 SUBSTITUTED 2-AMINO-CYCLOALKANECARBOXAMIDES AND THEIR USE AS CYSTEINE PROTEASE INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
EP-1453801-B1 SUBSTITUTED 2-AMINO-CYCLOALKANECARBOXAMIDES AND THEIR USE AS CYSTEINE PROTEASE INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
US-6759428-B2 SUCH AS N-((1,2)-2-(((CYANO(CYCLOPROPYL)METHYL)AMINO)CARBONYL) CYCLOHEXYL)-1H-INDOLE-2-CARBOXAMIDE; CATHEPSIN K INHIBITORS ROCHE PALO ALTO LLC 2004-07-06 US disclosed
US-6747053-B2 Heteroaryl nitriles ROCHE PALO ALTO LLC 2004-06-08 US disclosed
US-20040077646-A1 Indole nitriles ROCHE PALO ALTO LLC 2004-04-22 US disclosed
US-20030212097-A1 Heteroaryl nitriles ROCHE PALO ALTO LLC 2003-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212097-A1 Heteroaryl nitriles UACA, FPR1, GSTA1 CCKBR 1288/4885FAAH 249/4885SSTR3 1108/4885
US-20040077646-A1 Indole nitriles TPH1, IDO1, NAT1 CCKBR 754/4885FAAH 287/4885SSTR3 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.